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Abstract
Introduction After pancreatic surgery, up to 80% of patients will develop exocrine insufficiency. For enzyme supplementation to
be effective, prescribing an adequate dose of pancreatic enzymes is mandatory but challenging because the required dose varies.
Data on the practice of enzyme replacement therapy after surgery are lacking, and therefore, we conducted this analysis.
Methods An anonymous survey was distributed to members of the Dutch and German patient associations for pancreatic disorders.
The target population consisted of patients with chronic pancreatitis or pancreatic cancer who had undergone pancreatic surgery and
were using enzymes to treat exocrine insufficiency. Results were compared to a similar group of non-operated patients.
Results Ninety-one cases were analyzed (84 % underwent a resection procedure). The median daily enzyme dose was 6, and
25 % took three or less capsules. Despite treatment, 68 % of patients reported steatorrhea-related symptoms, 48 % adhered to
a non-indicated dietary fat restriction, and only 33 % had visited a dietician. The outcome was equally poor for the 91 non-
operated patients.
Conclusion Most patients suffering from exocrine insufficiency after pancreatic surgery are undertreated. To improve
efficacy, physicians should be more focused on treating exocrine insufficiency and educate patients to adjust the dose
according to symptoms and their diet.
Keywords Chronic pancreatitis . Pancreatic cancer .
Exocrine pancreatic insufficiency . Pancreatic surgery .
Pancreatic enzyme replacement
Introduction
In exocrine insufficiency, the pancreas is unable to deliver
sufficient quantities of digestive enzymes to the small
intestine. Because of the large residual capacity of the pan-
creas, exocrine insufficiency becomes clinically apparent
only when 90 % of the function is lost.1,2 After pancreatic
surgery, the exocrine function is determined by the under-
lying pancreatic disease and the chosen surgical procedure
(depending on the extent of the resection and the restoration
of gastrointestinal tract continuity).3,4 Postoperatively, exo-
crine insufficiency is observed in 65 to 80 % of the patients
with chronic pancreatitis.5,6 In patients with pancreatic can-
cer, exocrine insufficiency is found in 68 to 92 % before
surgery and in 80 % after surgery.7
Exocrine insufficiency leads to malabsorption, which
causes steatorrhea, weight loss, and malnutrition.8–11 It is
associated with deficiencies of the fat-soluble vitamins
(vitamin A, D, E, and K), magnesium, calcium, and essential
fatty and amino acids.12–15 To reduce morbidity and mortality,
patients should be treated with a sufficient dose of pancreatic
enzymes.16–19 In clinical practice, enzyme replacement thera-
py proves challenging because the optimal enzyme dose is
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highly variable, depending on the remaining pancreatic func-
tion, the postsurgical anatomy, and the dietary fat content.
Unfortunately, physicians are often not well informed about
the need to supplement exocrine insufficiency in a flexible and
patient-tailored manner. In addition, exocrine insufficiency is
frequently overlooked because the primary attention is direct-
ed towards treatment of the underlying disease. This may be
especially true for surgeons who are confronted with a patient
with pancreatic cancer because their main concern is to ex-
plore curative options.
Remarkably, data on the clinical practice of enzyme replace-
ment therapy in surgically treated patients are lacking. There-
fore, this survey was conducted to evaluate the daily practice of
enzyme replacement therapy in postoperative patients.
Methods
This prospective, cross-sectional study was approved by the
Medical Ethics Committee of the Erasmus University Med-
ical Center in Rotterdam. In 2010, an anonymous survey
was distributed among the members of the Dutch and Ger-
man patient associations for pancreatic disorders. The target
population consisted of surgically treated patients with
chronic pancreatitis or pancreatic cancer who were using
enzymes to treat exocrine insufficiency. We also assessed
the responding members who fulfilled the criteria of the
target population, but had not been operated upon.
The survey was distributed by mail and had to be returned
within 3 months. After 4 weeks, a reminder was sent out to the
members that had not responded. The survey contained free
field and multiple-choice questions and took about 10 min to
complete. The items evaluated in the survey were the daily
enzyme dose (recalculated as the number of capsules contain-
ing 25,000 FIP (Fidiration Internationale Pharmaceutique)
units of lipase), the timing of enzyme ingestion, the presence
of steatorrhea-related symptoms (bloating; abdominal cramps;
bulky, sticky, and fatty stools), referral to a dietician, and
restrictions in fat intake (either recommended by a physician
or dietician, or self-imposed).
Statistical analyses were conducted using SPSS 17.0.
Results were expressed as medians and percentiles using
the appropriate t tests or nonparametric tests for continuous
variables. For categorical data, the Χ² test was used.
Results
Two hundred and sixty-five members responded to the survey,
of which 182 (69 %) had chronic pancreatitis or pancreatic
cancer and were using pancreatic enzymes for exocrine insuf-
ficiency. The baseline characteristics of these 182 patients are
described in Table 1. Ninety-one of these patients had
undergone pancreatic surgery (84 % underwent a resection
procedure and 16 % a drainage procedure; Table 2). The
remaining 91 patients had not been operated upon.
The enzyme preparations used by the study population
were all enteric coated and of porcine origin, Creon in 52 %
(Abbott, Solvay Pharma), Panzytrat in 32 % (Tramedico,
Aptalis Pharma), and Pancrease in 16 % (Janssen-Cilag).
Eighty-five percent used a high-dose preparation
(25,000 FIP units of lipase). Twenty-four patients (26 %)
took the enzymes before their meal, 62 (68 %) during a meal,
and 11 (12 %) after a meal. Forty-nine patients (54 %)
reported to take additional enzymes when they had a snack.
After surgery, the reported median enzyme dose was six
capsules per day, and 23 patients (25 %) took three or less
capsules per day (Table 3). There was no difference in
dosing between the subgroups of patients who had under-
gone a pancreatic resection and a drainage procedure. De-
spite treatment, 62 cases (68 %) reported steatorrhea-related
complaints, and 36 (39 %) suffered from weight loss. From
the patients who took three or less capsules per day, 16
(70 %) suffered from steatorrhea and 11 (48 %) from weight
loss, versus 46 (51 %) and 23 (34 %) of the patients who
used more than three capsules per day (p value 0.769 and
Table 1 Baseline characteristics of 182 operated and non-operated






Age—median (IQR) 60 (49–68) 57 (50–67)
Male sex—n (%) 44 (48) 41 (45)
Chronic pancreatitis—n (%) 54 (59) 83 (91)
Pancreatic cancer—n (%) 37 (41) 8 (9)
Supplementation duration—
median mo (IQR)
54 (28–131) 60 (49–68)
Table 2 Type of surgical procedure in the 91 operated patients with






Type of surgical procedures
Whipple—n (%) 20 (37) 31 (84)
Distal pancreatectomy—n (%) 5 (9) 3 (8)
Pancreatic head resection—n (%) 14 (26) 1 (3)
Total pancreatectomy—n (%) – 2 (5)
Type of drainage procedures
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0.219, respectively). Only 33 patients (36 %) reported to
have visited a dietician for their exocrine insufficiency, and
44 patients (48 %) kept an unnecessary dietary fat restric-
tion, either prescribed by a physician or dietician, or self-
imposed. All these results were comparable to the results of
the non-operated patients.
Discussion
This study is the first to capture how postoperative patients
with exocrine insufficiency are being treated and gives an
insight in the clinical practice of pancreatic enzyme supple-
mentation. The results imply that, even in countries with a
well-organized health care system, the majority of patients
are undertreated.
Although steatorrhea-related symptoms may correlate
poorly with the objective measure of steatorrhea, we believe
we have gathered some valid data. Despite enzyme replace-
ment, most patients were still bothered by steatorrhea-
related complaints, although studies have shown that ade-
quate enzyme therapy can relieve these symptoms complete-
ly. Furthermore, guidelines stress that with the proper
amount of enzymes, patients should be able to maintain a
normal diet. In our study population, most patients were not
aware of this and tended to avoid fat. Interestingly, results
were equally poor for non-operated patients.
Apparently, surgeons as well as gastroenterologists fail to
achieve a satisfactory treatment response in many of their
patients. This poor outcome may be explained by the par-
ticular intricacies of pancreatic enzyme replacement therapy.
The enzyme dose needs to be individually adjusted based on
the residual pancreatic function and the dietary fat
intake.20–27 In addition, after surgery, the altered anatomy
should be taken into account. This variability in individual
dosage response and the lack of practice guidelines make it
difficult for physicians to prescribe the proper dose. Also,
publications on this subject are scarce, and therefore, physi-
cians are not well informed.
Furthermore, besides theoretical knowledge, effective
treatment requires ample diligence of the treating physician
to train patients in flexible dosing. However, enzyme sup-
plementation may not seem a major concern in patients with
chronic pancreatitis who are treated for severe pain. More-
over, in case of a life-threatening condition such as pancre-
atic cancer, treatment of exocrine insufficiency may seem
futile. Yet, even in these patients, steatorrhea-related symp-
toms and associated weight loss can be a tremendous bur-
den. A randomized trial by Bruno et al. proved that
treatment of exocrine insufficiency is beneficial in such
patients. Twenty-one patients with exocrine insufficiency
were treated for 8 weeks with either six capsules of a
high-dose pancreatic enzyme preparation per day, or a
placebo.16 All patients received dietary consultation. A sig-
nificant difference in body weight was observed; patients on
pancreatic enzymes gained 1.2 % (0.7 kg), whereas patients
on placebo lost 3.7 % (2.2 kg). In addition, the fat absorp-
tion coefficient in patients on pancreatic enzymes improved
by 12 %, whereas in placebo patients, it dropped by 8 %.
Also, guidelines published in Gut have recommended that
pancreatic enzymes should be used in exocrine-insufficient
patients with pancreatic cancer to maintain weight and in-
crease their quality of life.28
The anatomical changes resulting from pancreatic sur-
gery require careful consideration in the diagnosis and treat-
ment of maldigestion.29 First of all, the extent of the
pancreatic resection is an important denominator for the
development of exocrine insufficiency. In addition, the nor-
mal digestive physiology is altered in case of reconstructive
surgery after a Whipple’s procedure. This may lead to a
reduction in exocrine pancreatic secretion due to abnormal
postprandial CCK release. Also, asynchrony between gas-
tric emptying and pancreatic secretion in the small intestinal
lumen may develop, resulting in improper mixing of
enzymes and chyme, a phenomenon called secondary
Table 3 Treatment outcome of
enzyme replacement therapy in
91 surgically treated patients
with chronic pancreatitis and
pancreatic cancer and 91 non-
operated patients
aNumber of enteric-coated
capsules containing 25,000 FIP
units of lipase
Operated patients Non-operated patients





Enzyme dose/daya; 25 %
of patients
≤3 ≤4 ≤3 ≤3
50 % of patients ≤6 ≤6 ≤5 ≤4
75 % of patients ≤8 ≤8 ≤7 ≤6
Symptoms of
steatorrhea—n (%)
62 (68) 37 (69) 25 (68) 61 (67)
Weight loss—n (%) 36 (39) 19 (35) 17 (46) 35 (39)
Fat restriction—n (%) 44 (48) 28 (52) 16 (43) 52 (57)
Referral to dietician—n (%) 33 (36) 14 (26) 19 (51) 21 (23)
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exocrine insufficiency.30 Furthermore, changes in gastric
and duodenal acidity may influence the denaturation of
enzymes and the dissolution of enteric-coated mini-dose
units. Finally, after surgery, in particular after a Roux-en-Y
anastomosis or pancreaticoduodenectomy, malabsorption
may develop due to bacterial overgrowth.
Although studies have shown different gastric-emptying
profiles after conventional and pylorus-preserving pancreati-
coduodenectomy, long-term results have shown that enzyme
replacement therapy with enteric-coated preparations is effec-
tive postsurgically.31–33 Therefore, the pancreatic function
should be evaluated postoperatively. A fecal Elastase-1 test
should be routinely performed, also in asymptomatic patients,
because clinical signs of steatorrhea may be absent as patients
tend to limit fat intake to reduce symptoms. Pancreatic enzyme
supplementation should be considered in every patient with
proven exocrine insufficiency, irrespective of the underlying
disease or prognosis. Even in the case of asymptomatic exo-
crine insufficiency, treatment is indicated because studies have
shown that malnutrition may develop in these patients. More-
over, enzymes can also be effective in patients with clinical
signs of malabsorption without proven exocrine insufficiency
because secondary exocrine insufficiency may be present.
There are very few studies that address how pancreatic
enzyme replacement therapy should be dosed. Only one ran-
domized trial has compared the efficacy of a fixed enzyme
dosage to self-administration ad libitum according to fat in-
take in exocrine insufficient patients with chronic
pancreatitis.34 There was a significant increase from 5 capsu-
les per day during the fixed treatment period to 11 capsules per
day during the self-administration period. With this increased
dose, a significant decrease in steatorrhea-related symptoms
was observed. The authors concluded that efficacy is higher
when enzymes are self-dosed by patients in a flexible manner.
Despite the absence of an easy method to establish the
adequate dose of pancreatic enzymes, some guidelines can
be given. A reasonable starting dose is 50,000 to
75,000 units of lipase for a main meal and 25,000 units for
snacks. Subsequently, patients should be instructed to vary
the dose according to their dietary fat intake, up to a max-
imum of 16 capsules a day. They should be explained that
the presence of steatorrhea-related symptoms and weight
loss imply an insufficient dose of enzymes that needs to be
increased. The timing of the capsule ingestion is also im-
portant because the enzymes have to be mixed with the
chyme to be effective. Patients should be instructed to take
the enzymes during or right after a meal.20,35–38 Finally,
management of exocrine insufficiency can be greatly facil-
itated by dietary counseling from a well-trained, specialized
dietician. A dietician can teach patients the principles of
flexible dosing and prevent them from keeping unnecessary
dietary restrictions because many patients tend to avoid fat
out of fear for steatorrhea-related complaints.
When treatment response remains unsatisfactorily despite
optimal use of enzymes, other steps may be needed. To
improve therapeutic efficacy, inhibition of gastric secretion
(if gastric acid secretion is preserved) can be attempted by the
administration of a proton pump inhibitor. Also, capsules can
be opened prior to ingestion, or uncoated enzyme preparations
can be prescribed, as accelerated gastric emptying may pre-
vent timely dissolution. If the patient still does not have a
satisfactory treatment response, testing for bacterial over-
growth and celiac disease should be considered.
Our study was bound to certain limitations. First of all, due
to the design as an anonymous survey, which was required by
the medical ethical committee, certain information about the
patient population was unavailable. Therefore, we were un-
able to calculate the response rate, to provide information
about the lifestyle of patients, and the etiology and severity
of the pancreatitis or pancreatic cancer. Furthermore, data
could not be objectified in case of remaining questions or
uncertainties. For example, the outcome measure of weight
loss could have been influenced by other factors, such as the
underlying malignancy. Finally, a selection bias might have
occurred. After all, this survey was distributed among mem-
bers of a patient organization, who are generally highly moti-
vated and better informed. Also, complex pancreatic surgery
is mainly executed in tertiary referral centers, where treating
physicians are likely to be more experienced in diagnosing
and treating exocrine insufficiency. However, if this would be
the case, it only stresses our conclusions as results elsewhere
are expected to be even worse.
Conclusion
This is the first study to give insight in the daily practice of
pancreatic enzyme usage in patients with exocrine insufficien-
cy after pancreatic surgery. Our results indicate that a substan-
tial proportion of patients are underdosed and that there is
ample room for improvement. To accomplish this, physicians
should be attentive on treating exocrine insufficiency, also in
patients with an unfavorable prognosis. Patients should be
better educated in using pancreatic enzymes in a flexible
manner, depending on their meal composition. For this, in-
volvement of a well-trained, specialized dietician is desirable.
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